UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort

Bustaffa, M; Koné-Paut, I; Ozen, S; Amaryan, G; Papadopoulou-Alataki, E; Gallizzi, R; Carrabba, M; ... Semerano, LR; + view all (2022) The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort. Seminars in Arthritis and Rheumatism , 52 , Article 151957. 10.1016/j.semarthrit.2022.151957. Green open access

[thumbnail of Brogan_BROGANFMF_INT_paper_for Authors revision.pdf]
Preview
Text
Brogan_BROGANFMF_INT_paper_for Authors revision.pdf

Download (218kB) | Preview

Abstract

Introduction: New Eurofever/PRINTO classification criteria (EPCC) for Familial Mediterranean Fever (FMF) and other recurrent fevers have been recently developed, together with the classification of the pathogenicity of MEFV variants. Objectives: To evaluate the impact in real life of both the EPCC and INSAID pathogenicity classification of MEFV variants in the large international Eurofever FMF cohort. Methods: Baseline demographic, genetic and clinical data of FMF patients included in the Eurofever registry were evaluated. The EPCC and the 2018 INSAID classification for MEFV variants were applied in all eligible FMF patients. Results: Since November 2009, clinical information was available for 1012 FMF (532 males/480 females, 827 children/185 adults) from 119 centres. Complete data were available for 887 patients in whom 623 (70.2%) satisfied EPCC (EPCC+), while 264 (29.8%) did not (EPCC−). The majority of the EPCC− patients (172, 65.1%) displayed negative or non-informative genetics (monoallelic or biallelic benign variants, monoallelic variant of unknown significance). At baseline, colchicine was used in most of EPCC+ patients (88%) and in a lower percentage of EPCC− patients (69%, p < 0.0001), who were treated in a higher proportion with steroid or NSAID on demand (p = 0.003 and 0.008, respectively). Four percent of patients received Anti-IL-1 treatment. Conclusions: The combination of EPCC and the 2018 INSAID classification of MEFV variants is able to identify two distinct groups of patients, which differ in clinical characteristics, therapeutic approach and response to treatment. EPCC+ patients displayed the typical features of FMF, while EPCC− patients had a more variable phenotype with a lower percentage of response to colchicine.

Type: Article
Title: The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.semarthrit.2022.151957
Publisher version: https://doi.org/10.1016/j.semarthrit.2022.151957
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Autoinflammatory diseases, Classification criteria, Familial mediterranean fever, Genetic analysis, Recurrent fevers, Registry, Cohort Studies, Colchicine, Familial Mediterranean Fever, Female, Humans, Male, Mutation, Pyrin, Registries
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
URI: https://discovery.ucl.ac.uk/id/eprint/10148387
Downloads since deposit
127Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item